Literature DB >> 10583588

NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads.

S Ehlers1, S Kutsch, J Benini, A Cooper, C Hahn, J Gerdes, I Orme, C Martin, E T Rietschel.   

Abstract

Granuloma formation in response to mycobacterial infections is associated with increased expression of inducible nitric oxide synthase (NOS2) within granuloma macrophages and increased levels of nitrate/nitrite in the sera of infected mice. Continuous treatment with 5 mm or 10 mm l-N6-(1-imino-ethyl)-lysine (L-NIL), a selective NOS2-inhibitor, in acidified drinking water for up to 7 weeks consistently reduced infection-induced nitrate/nitrite to background levels in mycobacteria-infected BALB/c mice. Oral treatment with 5 mm L-NIL initiated at the time of infection significantly exacerbated growth of Mycobacterium tuberculosis, but had no effect on Mycobacterium avium colony-forming unit development in the liver, spleen and lungs of intravenously infected mice. In order to examine the role of nitric oxide in mycobacteria-induced granulomatous inflammation in the absence of any effect on the bacterial load, M. avium-infected mice were treated with 5 mm L-NIL from day 1 through 38 and the development of granulomatous lesions in the liver was assessed by histology, immunohistology and reverse-transcription-polymerase chain reaction (RT-PCR). Computer- and video-assisted morphometry performed at 4 and 7 weeks post-infection showed that treatment with L-NIL led to markedly increased number, cellularity and size of granulomatous lesions in infected mice regardless of the virulence of the M. avium isolate used for infection. Immunohistology of the liver revealed that in mice treated with L-NIL, the numbers of CD3+ T cells, CD21/35+ B cells, CD11b+ macrophages and RB6-8C5+ granulocytes associated with granulomatous lesions was increased. RT-PCR of the liver showed that in L-NIL-treated mice infected with M. avium, mRNA levels of tumour necrosis factor, interleukin-12p40, interferon-gamma, interleukin-10 and interferon-gamma-inducible protein-10 (IP-10) were up-regulated, while mRNA levels of interleukin-4, monocyte chemotactic protein-1 (MCP-1) and MCP-5 were similar to those in untreated control infected mice. When M. avium-infected mice were treated with 5 mm L-NIL between the 5th and 12th weeks of infection, similar changes in granuloma number and size were found in the absence of any effect on the bacterial load. These findings demonstrate that nitric oxide regulates the number, size and cellular composition of M. avium-induced granulomas independently of antibacterial effects by modulating the cytokine profile within infected tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583588      PMCID: PMC2326941          DOI: 10.1046/j.1365-2567.1999.00875.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  The role of macrophage activation and of Bcg-encoded macrophage function(s) in the control of Mycobacterium avium infection in mice.

Authors:  R Appelberg; A M Sarmento
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene.

Authors:  M S Gomes; M Flórido; T F Pais; R Appelberg
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

3.  Nitric oxide: an endogenous modulator of leukocyte adhesion.

Authors:  P Kubes; M Suzuki; D N Granger
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma.

Authors:  D Smith; H Hänsch; G Bancroft; S Ehlers
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

5.  Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway.

Authors:  C D Mills
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

6.  Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia.

Authors:  M J Hickey; K A Sharkey; E G Sihota; P H Reinhardt; J D Macmicking; C Nathan; P Kubes
Journal:  FASEB J       Date:  1997-10       Impact factor: 5.191

7.  Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine.

Authors:  F Y Liew; S Millott; C Parkinson; R M Palmer; S Moncada
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

Review 8.  Nitric oxide as a secretory product of mammalian cells.

Authors:  C Nathan
Journal:  FASEB J       Date:  1992-09       Impact factor: 5.191

9.  Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates.

Authors:  I E Flesch; S H Kaufmann
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  The multiplex function of nitric oxide in (auto)immunity.

Authors:  C Bogdan
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  24 in total

1.  Gamma interferon-induced T-cell loss in virulent Mycobacterium avium infection.

Authors:  Manuela Flórido; John E Pearl; Alejandra Solache; Margarida Borges; Laura Haynes; Andrea M Cooper; Rui Appelberg
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Regulation of granuloma fibrosis by nitric oxide during Mycobacterium avium experimental infection.

Authors:  Susana Lousada; Manuela Flórido; Rui Appelberg
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

3.  Mycobacterium tuberculosis pellicles express unique proteins recognized by the host humoral response.

Authors:  Patrick W Kerns; David F Ackhart; Randall J Basaraba; Jeff G Leid; Mark E Shirtliff
Journal:  Pathog Dis       Date:  2014-02-26       Impact factor: 3.166

Review 4.  Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium?

Authors:  Rui Appelberg
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection.

Authors:  John E Pearl; Egidio Torrado; Michael Tighe; Jeffrey J Fountain; Alejandra Solache; Tara Strutt; Susan Swain; Rui Appelberg; Andrea M Cooper
Journal:  Eur J Immunol       Date:  2012-09-26       Impact factor: 5.532

6.  Role of granulocyte/macrophage colony-stimulating factor in zymocel-induced hepatic granuloma formation.

Authors:  A A Wynn; K Miyakawa; E Miyata; G Dranoff; M Takeya; K Takahashi
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

7.  Differential requirement for interferon-gamma to restrict the growth of or eliminate some recently identified species of nontuberculous mycobacteria in vivo.

Authors:  S Ehlers; E Richter
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

8.  Early induction of humoral and cellular immune responses during experimental Mycobacterium avium subsp. paratuberculosis infection of calves.

Authors:  W R Waters; J M Miller; M V Palmer; J R Stabel; D E Jones; K A Koistinen; E M Steadham; M J Hamilton; W C Davis; J P Bannantine
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Sphingosine kinase-1 (SphK-1) regulates Mycobacterium smegmatis infection in macrophages.

Authors:  Hridayesh Prakash; Anja Lüth; Natalia Grinkina; Daniela Holzer; Raj Wadgaonkar; Alexis Perez Gonzalez; Elsa Anes; Burkhard Kleuser
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

10.  Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease.

Authors:  Mercedes Gonzalez-Juarrero; Luke C Kingry; Diane J Ordway; Marcela Henao-Tamayo; Marisa Harton; Randall J Basaraba; William H Hanneman; Ian M Orme; Richard A Slayden
Journal:  Am J Respir Cell Mol Biol       Date:  2008-09-11       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.